Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a
neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of
this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate
the efficacy and safety of Shuxuening injection in the treatment with intravenous
thrombolysis in patients with ischemic stroke.